Related Experiment Video
Updated: Feb 2, 2026

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
Published on: February 3, 2023
Expression of programmed death ligand 1 and 2 in adrenocortical cancer tissues: An exploratory study
John F Tierney1, Alyx Vogle1, Jennifer Poirier1
1Rush University Medical Center, Department of Surgery, Division of Surgical Oncology, Chicago, Illinois.
Background:
Inhibition of the interaction of programmed death 1 with programmed death ligand 1 and 2 has been used successfully for treatment of multiple advanced cancers, but expression has not been studied in adrenocortical carcinoma. In this study, we investigated programmed death ligand 1 and 2 expression in adrenocortical carcinoma to determine the potential usefulness of checkpoint inhibitors in these malignant neoplasms.
Methods:
A total of 56 tissue samples from patients with adrenocortical carcinoma (34) and benign adrenal tissues (22) were identified. Immunohistochemistry was performed for programmed death ligand 1, programmed death ligand 2, and CD8 and scored for membranous staining on adrenal and stromal tissue according to the immunoreactive score and absolute percentage, respectively. Descriptive statistics, a Mann-Whitney U test, and Fisher exact tests were calculated.
Results:
In total, 15 adrenocortical carcinoma (44%) stained positive for programmed death ligand 2 and 1 adrenocortical carcinoma for programmed death ligand 1 (P = .03). Adrenocortical carcinoma samples were more likely to express programmed death ligand 2 on tumor cells or in stromal tissues than benign samples (OR = 2.3, P = .03). There was no relationship between programmed death ligand 2 and CD8 expression (P = .08). There were also no relationships between programmed death ligand 2 or CD8 expression and tumor characteristics.
Conclusion:
Programmed death ligand 2, but not programmed death ligand 1, is expressed commonly in adrenocortical carcinoma samples. The utility of certain checkpoint inhibitors should, therefore, be evaluated in further studies.
Insights
Programmed death ligand 2 is commonly expressed in adrenocortical carcinoma, unlike programmed death ligand 1. Further studies should evaluate checkpoint inhibitors for this cancer.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Immune checkpoint inhibitors targeting programmed death 1 (PD-1) interactions are effective in advanced cancers.
- Expression of PD-1 ligands (PD-L1 and PD-L2) has not been previously studied in adrenocortical carcinoma (ACC).
Purpose of the Study:
- To investigate the expression of programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2) in adrenocortical carcinoma.
- To determine the potential utility of immune checkpoint inhibitors in treating ACC.
Main Methods:
- Analyzed 56 adrenal tissue samples (34 ACC, 22 benign).
- Utilized immunohistochemistry to detect PD-L1, PD-L2, and CD8 expression.
- Scored membranous staining and performed statistical analyses (Mann-Whitney U, Fisher exact tests).
Main Results:
- Programmed death ligand 2 (PD-L2) was expressed in 44% of ACC samples, while PD-L1 expression was found in only one ACC sample (P=.03).
- ACC samples showed significantly higher PD-L2 expression in tumor or stromal cells compared to benign samples (OR=2.3, P=.03).
- No significant association was found between PD-L2 expression and CD8 levels or tumor characteristics.
Conclusions:
- Programmed death ligand 2 (PD-L2) is frequently expressed in adrenocortical carcinoma, suggesting potential therapeutic relevance.
- Programmed death ligand 1 (PD-L1) expression is rare in ACC.
- Further research is warranted to evaluate the efficacy of checkpoint inhibitors targeting PD-L1/PD-L2 pathways in ACC treatment.
Related Concept Videos
Predicting Products: SN1 vs. SN2
With increased substitution on the alkyl halide,...
Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Metal-Ligand Bonds
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...
Ligand Binding and Linkage
1° Amines to Diazonium or Aryldiazonium Salts: Diazotization with NaNO2 Overview
The nitrous acid is unstable. Hence, it is formed in situ from a solution of sodium nitrite and cold aqueous acids such as hydrochloric or sulfuric acid. In an acidic solution, the –OH group of nitrous acid undergoes protonation to give oxonium ion, followed by...
1° Amines to Diazonium or Aryldiazonium Salts: Diazotization with NaNO2 Mechanism

